Investor Relations

Jan Westerhüs
Investment Principal, Robert Bosch Venture Capital GmbH

Based in the Frankfurt office Jan Westerhüs is an Investment Principal with RBVC. He is involved in all phases of the investment process from preliminary evaluation to assisting management during the investment period. Prior to this position he was responsible for Bosch Corporate Strategy in the Asia Pacific region, based in Shanghai. He gathered extensive experience in strategy consulting before joining the Bosch Group. Jan holds a joint master degree in engineering and business administration (Dipl.-Wirtsch.-Ing.) from the Technical University of Darmstadt, Germany. He speaks German, English, Spanish fluently and has a basic knowledge of Mandarin.

Peter Meekin
Managing Director, Trident Capital
Peter Meekin joined Trident Capital as a Managing Director in 1999. He has more than 20 years of experience in software, information services, and technology consulting. Prior to joining Trident Capital, he was Vice President of Venture Development at Enterprise Associates, LLC, the venture capital division of IMS Health. He has also held senior technology and management positions with Dun & Bradstreet Corporation, Lotus Development Corporation and IBM. In addition, Mr. Meekin has hands-on entrepreneurial experience having launched three start-up companies in the software and consulting industries.

Mr. Meekin's current board memberships include Aethon, Arxan Technologies, iRobot (IRBT), Spire, TriCipher, Vidient and Voltage Security, Inc. He formerly served as a director of Berkeley Enterprise Partners, Inc. (acquired by Extraprise, Inc.), Circles (acquired by Sodexho Alliance), Customer Analytics, Inc. (acquired by Exchange Applications (EXAP)), Cymfony (acquired by TNS Media Intelligence), ELetter, Inc., ESS Software, Inc., Sygate Technologies (acquired by Symantec), Tablus, Inc. (acquired by RSA, The Security Division of EMC (NYSE: EMC) and Thor Technologies (acquired by Oracle).

Ron Taylor
Chairman and CEO, Asteres
Former Chairman, CEO, and Founder, Pyxis Corporation
A pioneer in healthcare pharmacy technology, Ron Taylor founded Pyxis Corp. in 1987 as one of the industry's first companies to specialize in integrated software and hardware technology solutions for hospitals and long-term care facilities. He took the venture capital financed company public in 1992 and set a new standard for the safe delivery of drugs and supplies nationwide. Mr. Taylor served as Pyxis Chairman and Chief Executive Officer until the firm was purchased by Cardinal Health, Inc. (NYSE: CAH) in 1996 for a record $1 billion.

After the sale and transition of Pyxis to Cardinal Health, Taylor spent several years as General Partner at Enterprise Partners Venture Capital. He is currently an independent investor and serves as Board Director for three publicly traded companies, Watson Pharmaceuticals, Inc. (NYSE:WPI), ResMed Corporation (NYSE: RMD) and WestCoast Hospitality Corp. (NYSE: WEH). Mr. Taylor also serves as Foundation Chair at the University of California, San Diego and remains Chairman of The Board for three privately held companies, Asteres Inc., 3E Company and EMNS Corporation.

Layton Crouch
Managing Director, Pacific Venture Group
Layton Crouch has been a successful venture executive in the healthcare industry for over 35 years. Mr.Crouch serves on the board of PVG companies AD PathLabs and LifeMasters Supported Self Care and is responsible for PVG's investments in Long Term Care Group, CHD Meridian and Vasca.

Significant previous management and investment experience includes an eight-year term as President and CEO of UniHealth Ventures. There he led the start-up development of CareAmerica Health Plans (which grew to $500 million in revenue prior to sale), the development and profitable sale of Medcomm Management, and the successful merger of CliniShare and National In-Home Health, which included dialysis, homecare and pharmacy services.

Mr.Crouch also directed the acquisition of the assets of six medical groups and IPAs representing over 2,000 physicians and combined revenues of $150 million, which formed a physician management services company. Additional companies developed/directed by Mr. Crouch include activities in managed healthcare IT and managed care TPA/contracting. Prior to UniHealth Ventures, Mr. Crouch served in numerous executive positions in hospitals, including serving as a hospital CEO and regional CEO.

Donald Jones
Managing Director, Draper Triangle Ventures
Donald Jones is a Managing Director of Draper Triangle Ventures. He is a nationally recognized entrepreneur and investor with over 30 years of experience in growing early stage companies. Mr.Jones was the founder and CEO of four highly successful technology companies — International Cybernetics Corporation, Control Systems Research, Technology Recognition Corporation and IndustryNet.

Mr.Jones is a director of numerous portfolio companies and has also served on the boards of several publicly held companies. He endowed the Center for Entrepreneurship at Carnegie Mellon University. Jones is an electrical engineering/computer science graduate of the University of Pittsburgh and is an adjunct professor at Carnegie Mellon University's Graduate School of Industrial Administration.

Sean McDonald
President and CEO, Precision Therapeutics
Former President and Founder, Automated Healthcare
Sean McDonald is the founder and past president of McKesson Automated Healthcare, a venture-backed company, sold to McKesson in 1996 for $65 million. He developed a centralized automated drug distribution system for hospital pharmacies. Mr.McDonald is now the president of Precision Therapeutics, a company that provides comprehensive, personalized, cancer management information to the medical and biopharmaceutical communities.

He received a BS in Engineering from the University of Pennsylvania (1982) and an MS in Electrical Engineering and Computer Science from the University of Florida (1985). Mr.McDonald received a Smithsonian Institution award for heroic achievement in information technology. He is Chairman of the Pittsburgh Technology Council and has served on the boards of several companies.

Kai Deusch
General Partner, Nexus Medicis Capital
Kai Deusch founded Medicis in 1994 to primarily provide consulting and contract research services in pre-clinical and clinical drug development. From 1999 on Medicis focused on principal investments and consulting services in healthcare transactions and business development.

Mr. Deusch has more than 20 year's professional experience in the Healthcare & Life Science Sector. He has been a partner at Apax Partners (2001-2002) with responsibility for the Healthcare Sector in Germany, Austria and Switzerland, partner in an intellectual property commercialization firm and founder & CEO of a Biotech Venture Capital firm that he successfully sold in 2001, management consultant in the Healthcare Practice of McKinsey & Company (1996-1999) and an internist with specialization in hepatogastroenterology & immunology.

He focuses on transactions in the area of Healthcare Services & Care Provision, Medical Technologies, Pharmaceuticals, Biotech and other Life Sciences.

Mr. Deusch studied Biology and Human Medicine at the Universities of Minneapolis, Mainz and London. He earned a B.Sc. in Biology, an MD (Dr. med.) in Human Medicine and qualified as a board certified Internist and an Associate Professor of Medicine at Technical University in Munich.

David Ward
General Partner, Salix Ventures
David Ward founded Salix Ventures with Chris Grant in 1997 and works in the Nashville, TN office. Prior to Salix, Mr.Ward was instrumental in the start-up and growth of two companies. As Vice President of Development at MedCath (Nasdaq: MDTH), a cardiovascular services provider, he was instrumental in conceiving, planning and executing the company's strategy for developing specialty heart hospitals, the first independent, freestanding specialized facilities in the United States dedicated to cardiovascular care.

Mr.Ward commenced his career at Bain Capital and was part of a team that conceived, developed, and implemented the business plan for MediVision. As Director of Development and then Vice President of Operations, he acquired, developed and later managed, numerous eye surgery centers and their affiliated practices.

After MediVision was acquired by Medical Care International, Ward served as Medical Care's Vice President of Managed Care. He graduated Phi Beta Kappa from Stanford University in 1979 with an AB in economics and received his JD and MBA from Stanford University in 1983.

Aldo Zini
President & CEO, Aethon
Aldo Zini has been at the forefront of the technology revolution in hospital patient safety for more than 15 years, instrumental in driving change into a marketplace attached to the status quo. He continues that leadership as President and CEO of Aethon, a robotic engineering company that has developed an innovative automation platform to improve supply chain logistics. Aethon's current focus is healthcare, where its core product TUG is being used to automate the delivery of goods (meds, supplies, meals, equipment, etc.) in hospitals.

Zini's successes began long before taking the helm at Aethon. His contributions to technology-driven companies have led to acquisitions worth more than a quarter of a billion dollars.

From 1991-96, he was the Vice President of Sales and Marketing for Automated Healthcare, which developed the first robotic medication dispensing system for hospitals (ROBOT-Rx) and was acquired by McKessonHBOC in 1996 for $67 million. He joined the founder during the early stage startup of this company and played a key role in VC funding, company and product development, product launch, sales and marketing.

From 1996-99, Zini assumed corporate responsibilities with McKessonHBOC as Senior Vice President of Marketing, where his Institutional Division's annual sales grew from $1 billion to $5 billion. Zini played a key role in building this company into one of the largest success stories in Pittsburgh. Automated Healthcare (now McKesson Automation Group) has generated more revenue and employed more people than any other technology company in the region over the last 15 years.

Before joining and investing in Aethon, he was Senior Vice President of Sales & Marketing for TechRX, the largest provider of software solutions to the pharmacy industry, which was sold to NDC Corporation for over $200 million.

In 2002, Zini invested in the start-up of Aethon — founded by robot entrepreneur Henry Thorne — and joined the company to lead its sales and marketing efforts.  Soon after Aethon's first institutional funding, Zini became the company's President and CEO.

Zini owns several patents in medication dispensing technology, and is credited with the development of key methodologies in quantifying the value proposition for several technology platforms deployed in hundreds of hospitals across the country.

Zini received a BS in Industrial Engineering from the University of Pittsburgh and graduated with high honors from Carnegie-Mellon (1987), where he received a Master's in Public Management (Health Systems IT).

Ryan Schuler
Investment Director, Ascension Health Ventures
Ryan Schuler is an Investment Director at Ascension Health Ventures, a strategic venture capital fund sponsored by four of the nation's largest Catholic health systems. Mr.Ryan joined AHV from A.G. Edwards & Sons' mergers and acquisitions group. Prior to his tenure at A.G. Edwards, Mr. Schuler was an associate at PricewaterhouseCoopers where he worked in the transaction support and audit practices. He earned a B.S. from Christian Brothers University and an M.B.A. from The Olin School of Business at Washington University.

Current board services include: Aethon, Inc., Haven Behavioral Healthcare, Inc., Impulse Monitoring, Inc., SeQual Technologies, Inc. SterilMed, Inc.

Daniel C. Lubin
Managing Partner, Radius Ventures
Daniel C. Lubin is a Managing Partner of Radius Ventures, which acts as the Investment Advisor to the Radius Funds. Previously, Mr. Lubin was a Director in the Investment Banking Division of Schroder Wertheim & Co., where he shared responsibility for managing the Health Care Group. He co-founded and was a Managing Director of KBL Healthcare Inc., a health and life sciences venture capital and investment banking organization, and served as President and Chief Operating Officer of KBL Healthcare Acquisition Corp, a publicly-traded Specified Purpose Acquisition Company (SPAC). His prior affiliations include Manufacturers Hanover Trust and the Center for Strategic and International Studies (CSIS), where he served as Special Assistant to the Chairman. He was a founder of Cambridge Heart, Inc. and currently serves on the board of directors of Management Health Solutions, Inc., a Radius portfolio company. He also serves on the Board of Trustees of The Haverford School and was recently appointed to the National Counsel of Advisors of the Center for the Study of the Presidency. Daniel earned a B.S. cum laude in Foreign Service from the Georgetown University School of Foreign Service and an M.B.A. with honors from Harvard Business School.

Gregory Zaic
General Partner, Nexus Medical Partners
Greg Zaic has been a venture capitalist primarily investing in the medical/biotech areas since 1983 and has served on numerous boards of directors, for both private and public companies, typically as lead investor and occasionally as acting CEO. As a general partner of Nexus Medical Partners, a Boston-based venture capital firm focused on medical devices and life science investments, he currently serves on the Board of Sabal Medical. Prior to joining Nexus, Mr. Zaic was a general partner of Prince Ventures, an independent, medically focused, venture capital partnership managing six funds. Before Prince, Mr. Zaic was a Vice President with The Vista Group, focusing on health care and medical products investment opportunities. Notable past investments include Biodel Corporation (re-formulated insulin), Infusion Systems (disposable IV administration devices), Focus Healthcare (HMO/workmen's compensation), PerSeptive Biosystems (bioseparations), and GenVec (gene-based therapeutics).

Mr. Zaic's started his career at Baxter Travenol Laboratories, Inc. where he managed the Special Products Division. He also played important roles in the introduction of two major new products for Baxter: Continuous Ambulatory Peritoneal Dialysis ("CAPD") and the hollow fiber dialyzer.

Mr. Zaic received a B.S. degree (magna cum laude, Phi Beta Kappa) in aerospace and mechanical engineering from Princeton University, an M.S. in mechanical engineering and an M.S. in management, both from the Massachusetts Institute of Technology.